Skip to main content

NICE

Volume 449: debated on Monday 11 September 2006

To ask the Secretary of State for Health which drugs were not approved by the National Institute for Health and Clinical Excellence which were assessed to have a cost per quality-adjusted-life-year of between £30,000 and £35,000 in each year since 2000; and if she will make a statement. (87745)

[holding answer 24 July 2006]: An analysis has been undertaken of drugs not approved by the National Institute for Health and Clinical Excellence (NICE), taking into account appraisals published between 1 January 2000 and 27 July 2006. Of the drugs appraised but not approved by NICE, none fell exactly into the cost quality-adjusted-life-year (QALY) range of between £30,000 and £35,000, although NICE’s appraisal of Anakinra for rheumatoid arthritis (published in November 2003) identified a wide potential cost per QALY range of between £20,000 and £952,000. Further information on this appraisal can be found on NICE’s website at www.nice.org.uk